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Abstract Our aim was to examine the association
between serum dehydroepiandrosterone sulfate (DHEAS)
at baseline and BMD change at the femoral neck (FN) and
lumbar spine (LS) in postmenopausal women during a
15-year follow-up. All participants were from the Ching-
ford Study. BMD at the FN and LS were measured eight
times during the 15-year follow-up by dual-energy X-ray
absorptiometry. DHEAS at baseline was measured using
radioimmunoassay. Data on height, weight, and hormone-
replacement therapy (HRT) status were obtained at each
visit. Multilevel linear regression modeling was used to
examine the association between longitudinal BMD change
at the FN and LS and DHEAS at baseline. Postmenopausal
women (n = 1,003) aged 45–68 years (mean 54.7) at
baseline were included in the study. After adjustment for
baseline age, estradiol, HRT, and BMI, BMD at the FN
decreased on average 0.49% (95% CI 0.31–0.71%) per
year; and the decline was slowed down by 0.028% per
squared year. Increase of DHEAS (each micromole
per liter) was associated with 0.49% less bone loss at the
FN (95% CI 0.21–0.71%, P = 0.001). However, this
strong association became slightly weaker over time.
Similar but weaker results were obtained for LS BMD. Our
data suggest that high serum DHEAS at baseline is asso-
ciated with less bone loss at both FN and LS and this
association diminishes over time. The nature of the asso-
ciation is unclear, but such an association implies that, in
managing BMD loss, women might beneﬁt from main-
taining a high level of DHEAS.
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Osteoporosis is deﬁned as a systemic skeletal disease
characterized by low bone mass and microarchitectural
deterioration of bone tissue, with consequent increases in
bone fragility and susceptibility to fractures [1, 2]. It affects
4–6 million postmenopausal white women in the United
States [3], and costs US $17 billion per year in direct
expenditure [4]. In the United Kingdom, osteoporosis costs
the National Health Service £940 million annually [2].
Osteoporosis is deﬁned clinically by the measurement of
bone mineral density (BMD), which remains the single best
predictor of primary osteoporotic fracture [5]. BMD
declines with increasing age, and the rate of decline is more
pronounced after menopause [6]. This decline can be
attributed to a number of factors: age, genetics, estrogen
deﬁciency, adverse lifestyle factors, or the prolonged use of
certain medication [7].
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are the most abundant circulating steroids. They are
secreted by the adrenal glands, decline with increasing age,
and have been implicated in a variety of age-related
pathophysiologic conditions including osteoporosis [8].
DHEA may have a role in protecting against BMD loss.
Postulated mechanisms include its conversion to androgen
and estrogen, alteration in hormone–receptor sites, and
regulation of enzymatic activity, all plausibly related to
bone metabolism [9]. Several studies have examined the
relationship between DHEA or DHEAS and osteoporosis
but with conﬂicting results [10–15]. This discrepancy could
be due to small sample size, heterogeneity of the study
populations, or cross-sectional design.
We utilized a longitudinal study design to examine the
association between serum DHEAS level at baseline and
BMD change over a 15-year follow-up in a large popula-
tion-based sample.
Subjects and Methods
Study participants were from the Chingford Study, a well-
described prospective population-based longitudinal study
of osteoarthritis and osteoporosis, comprising 1,003
women aged 43 years or above at entry, derived from the
age/sex register of a large general practice in Chingford,
north London. All the women lived within 5 miles of the
general practice, 98% of the women were white, and they
were predominantly middle class. Participants were similar
to women in the UK general population in terms of weight,
height, and smoking characteristics [16]. The study was
approved by the local ethics committee, and written con-
sent was obtained from each woman and has been descri-
bed in detail previously [16, 17].
DXA Scan
BMD was measured at the FN and LS at L1–L4 by dual-
energy X-ray absorptiometry (DXA; Hologic QDR 1000
for year 1 to year 3; Hologic QDR 2000 for year 4 to year
6; Hologic Delphi W for year 8 to year 10, and Hologic
Discovery for year 15; Hologic, Waltham, MA). A cross-
calibration was performed each time the machine was
upgraded. The cross-calibration involved scanning 30
patients on the old scanner and then again on the new one
on the same day. The coefﬁcient of variation for inters-
canner variation was 0.05% for BMD. Intrascanner repro-
ducibility, expressed as a coefﬁcient of variation from
duplicate measurements in healthy volunteers 1 week
apart, was 1.6% at the FN and 0.8% at the LS. Quality
control was performed regularly using a phantom to ensure
the reliability of the densitometer. All BMD measurements
were performed by a standardized protocol.
DHEAS Measurement
Serum samples were collected without any special patient
preparation requirements at the ﬁrst visit and stored at
-45C in a freezer until assayed. Serum DHEAS levels
were measured by radioimmunoassay (RIA) from the same
batch—a nonextraction, nonchromatographic method using
125I ligand as described previously [18]. The within- and
between-assay precisions were 4–10% and 6–14%,
respectively.
Other Measurements
At each biannual visit, height and weight were measured
and body mass index (BMI, weight [kg]/height [m
2]) was
calculated. In addition, information on smoking (never-
smokers, ex-smokers, and current smokers), physical
activity (inactive, moderately inactive, moderately active,
and active), diet (milk pints, ounce of cheese, yoghurt pots)
per week, estradiol, polypharmacy (current medication for
blood pressure, diabetes, diuretics, and thyroid), family
history (arthritis at hand and knee of child, mother, father,
brother, sister, aunt, and grandmother), and rheumatoid
arthritis (RA) was collected at the ﬁrst visit. All women
completed a standardized, nurse-administered question-
naire on medical history for a number of known risk factors
for osteoporosis. Medication information was detailed,
particularly for those drugs that inﬂuence bone loss such as
bisphosphonates and steroids. Use of hormone-replacement
therapy (HRT) was assessed, and women were classiﬁed as
‘‘current’’ and ‘‘no HRT’’ use for each visit year except
year 5.
Statistical Analysis
Since a series of BMD measurements during the 15-year
follow-up period were available and the number of
measurements and their time interval differed across
individuals, a multilevel regression model for longitudinal
data was chosen for the analysis. Repeated measures of
BMD at the FN and LS, sufﬁciently normally distributed,
taken on a maximum of eight occasions per participant
between baseline and the most recent clinical visit were
used as outcomes in the analyses. A time variable, mea-
sured in years since baseline, indicated when each mea-
surement was taken and represented follow-up time. The
model allowed the investigation of changes in the inﬂu-
ence of DHEAS on BMD over time by including
DHEAS-by-time interaction terms. The coefﬁcient for the
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123DHEAS variable then indicated its inﬂuence on BMD at
time zero (thus, baseline BMD), while the interaction
term indicated the inﬂuence of DHEAS on BMD change
per year from baseline (slope). These models account for
within-subject correlation between repeated measures and
allow for incomplete outcome data as long as a missing-
at-random process can be assumed. Therefore, all partic-
ipants with at least two BMD measurements make a
contribution to the estimates of association. The repeated
measures of BMD were modeled to represent a linear
change of BMD over time (slope). Nonlinear (time
squared) changes of BMD were also considered; this was
signiﬁcant and, therefore, included in the model. The
basic model was therefore reduced to include baseline
DHEAS, time, time squared, and the DHEAS-by-time
interaction. Wald tests were performed to assess levels of
signiﬁcance for the ﬁxed-effect parameters. The model ﬁt
was evaluated by a likelihood ratio test (LRT). Based on
the LRT, a random intercept model ﬁtted the data well
compared to other possible models. This allowed an
estimate of the variability across individual intercept and
intraclass correlation. Separate models were produced for
the FN and LS BMD. To investigate whether the asso-
ciations between baseline DHEAS and BMD at both sites
were confounded, age, estradiol at baseline, and time-
varying HRT and BMI as covariates were added to the
model. Since DHEAS was not associated with smoking,
physical activity, diet, polypharmacy, family history, and
RA, these variables were not included in the ﬁnal model.
From the ﬁnal adjusted model, predicted average BMD
trajectories over the follow-up time were also graphically
presented by baseline DHEAS interquartile ranges.
The model ﬁt was as follows:
BMDij ¼ b00 þ U0j

þb10DHEASj þ b20TIMEij
þ b30 DHEASj   TIMEij

þ b40TIME2
ij þ Eij
where BMDij denotes BMD at the FN or LS on measure-
ment occasion i (i = 1–8) of subject j (j = 1 - n),
DHEASj was DHEAS at the baseline, and TIMEij and
TIMEij
2 were deﬁned as the linear and quadratic forms of
the time in years after baseline at which each measurement
was taken, respectively. The terms U0j and Eij, denoting the
random intercept and error components, were assumed to
be normally, independently, and identically distributed
with mean zero and variance ru0
2 , re
2, respectively.
The intraclass coefﬁcient of the BMD that attributed to
subject effect (level 2) was estimated using the formula
qðYij=XijÞ¼
r2
u0
r2
u0þr2
e.
A coefﬁcient estimate was considered statistically sig-
niﬁcant if its P value (two-sided) was\0.05. All statistical
analyses were performed using STATA/SE version 10 for
Windows (StataCorp, College Station, TX).
Results
A total of 1,003 postmenopausal women with a mean age
of 54.7 years (range 45–68) at baseline participated in the
study. Thirty-three women were lost to follow-up (1 died,
14 moved, 5 withdrew, and 13 unknown) after the year 2
visit. By the year 15 visit, 111 women had died, 21 were
unable to attend for review, and 217 were lost to follow-up.
However, the majority of them (n = 301) were still
included in the analysis as they had baseline serum
DHEAS measurements and multiple DXA measures.
Only four women were on calcium and/or vitamin D
supplementation at baseline, but 178 women were at year
15. At years 10 and 15, there were 52 and 145 women
reported to be on either bisphosphonates or steroids,
respectively; and they were excluded from the analysis
after this point. The average duration of HRT use was
27 months for current HRT users.
Women were invited to come back for examination
every year, and a DXA scan was performed at baseline and
years 2, 3, 4, 5, 6, 8, and 10. On average, women had their
BMD measured at the FN and LS six times. There were
953 participants who had at least two FN BMD measure-
ments and 947 for LS BMD. Seventy-ﬁve subjects had no
baseline DHEAS measurements. The mean baseline BMD
was 0.79 and 0.98 g/cm
2 at the FN and LS, respectively,
and the mean baseline DHEAS was 3.99 (lmol/L)
(Table 1). Baseline DHEAS decrease with increasing
baseline age (q =- 0.23, P\0.0001), positively corre-
lated with baseline estradiol (q = 0.1, P = 0.007) and was
signiﬁcantly lower in current HRT users than nonusers
(P = 0.002). Means and ranges at different baseline age
categories were calculated and reported (Table 1).
Descriptive statistics at each visit of the study population
are presented in Table 2.
The ﬁnal analyses were restricted to people who had
baseline DHEAS measurements and at least two DXA
scans (n = 887 for FN and n = 879 for LS). There was no
signiﬁcant difference in baseline BMD at the FN and LS,
age, BMI, and HRT use between people with and without
DHEAS measurements (all P[0.05). However, those who
had only one DXA scan,\6% of the total study subjects,
were excluded from the analysis and were signiﬁcantly
older and heavier and had higher DHEAS levels than those
who had at least two DXA scans and were included in the
analysis (all P\0.02).
The results of the unadjusted and adjusted associations
between DHEAS and BMD change at FN and LS are
presented in Tables 3 and 4, respectively. BMD at the FN
decreased 0.45% (95% CI 0.30–0.60%) per year, and the
rate of decline was slowed down by 0.025% per squared
year (Table 3, Fig. 1). The serum level of DHEAS at
baseline was strongly and positively associated with the FN
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liter) was associated with 0.92% less bone loss at the FN
(95% CI 0.56–1.27%, P\0.0001). However, this strong
association became slightly weaker over time by 0.017%
(95% CI 0.0036–0.031%) per year as indicated by a sig-
niﬁcant DHEAS-by-time interaction (P = 0.013) (Table 3).
The negative and signiﬁcant interaction between DHEAS
and time reﬂects a small change in the degree to which
baseline DHEAS predicts bone loss at the FN during the
follow-up. The signiﬁcance remained after adjustment for
age and estradiol at baseline and time-varying BMI and
HRT (fully adjusted beta = 0.49%, 95% CI 0.21–0.71%,
P = 0.001), and all covariates were signiﬁcant in the
model, as expected (Table 3). The results remained the
same when the analyses were restricted to those women
who were never on HRT during the 15-year follow-up.
Figure 1 illustrates the average FN BMD trajectories over
time by baseline DHEAS interquartile ranges, which were
predicted from the ﬁnal adjusted multilevel model.
The variance component corresponding to the random
intercept is 0.014. Since this estimate is substantially larger
than its standard error (0.00068), there appears to be sig-
niﬁcant variation in the between-subject means. The two-
variance components can be used to partition the variance
across levels. The intraclass correlation coefﬁcient or the
proportion variance at the person level is estimated as
q = 0.94, meaning that roughly 94% of the variance of the
FN BMD measures were attributable to the subject level;
about 6% is variance within individuals across time. This
suggested that the variance within an individual across time
does not account for much of the additional variance of the
FN BMD.
Similarly, BMD at the LS decreased 0.46% (95% CI
0.31–0.60%) per year, and the rate of decline was slowed
down by 0.038% per squared year (Table 4, Fig. 2). The
serum level of DHEAS at baseline was strongly and pos-
itively associated with the LS BMD at baseline. Increase of
DHEAS (each micromole per liter) was associated with
0.72% less bone loss at the LS (95% CI 0.35–1.06%,
P\0.0001). However, this strong association became
slightly weaker over time by 0.037% (95% CI 0.023–
0.052%) per year as indicated by a signiﬁcant DHEAS-by-
time interaction (P\0.0001) (Table 4). The association
became weaker after adjustment for other covariates includ-
ing age and estradiol at baseline and time-varying BMI and
HRT (fully adjusted beta = 0.29%, 95% CI –0.038% to
0.56%, P = 0.078) (Table 4). However, the association
became stronger (P = 0.02) when the analyses were
restricted to those women who were never on HRT during
the 15-year follow-up. Figure 2 shows the average LS
BMD trajectories over time by baseline DHEAS inter-
quartile ranges, which were predicted from the ﬁnal
adjusted multilevel model. The graphs, at different quar-
tiles, start to converge slowly over the follow-up time,
implying that the effect of baseline DHEAS on LS BMD
loss diminishes over time.
The ﬁxed-effect model estimates the repeated-measures
variance as 0.0018 (within-subject variability) and the
person level (between-subject variability) as 0.023. This
estimates the total LS BMD variance as 0.025. The intra-
class correlation at the person level is estimated as
q = 0.93. This implies that about 93% of the variance in
the LS BMD measures was variance between individuals
(subjects) and that about 7% was variance within individ-
uals across time.
Discussion
This large prospective population-based study examined
the association between DHEAS level at baseline and
BMD change at the FN and LS in postmenopausal women
over a 15-year follow-up period. The data suggest that
serum level of DHEAS at baseline is strongly associated
with BMD but the association became slightly weaker over
time. Although the relationship between DHEAS and BMD
at the FN and LS was reduced after adjusting for age and
estradiol at baseline and time-varying BMI and HRT, an
independent effect on BMD was still apparent at both sites.
Further, women who had higher DHEAS levels at baseline
Table 1 Descriptive summary of baseline DHEAS and BMD at both sites at different baseline age categories
Variable Baseline age (years)
Age\50 50 B Age\55 55 B Age\60 Age C 60
Mean (n) Range Mean (n) Range Mean (n) Range Mean (n) Range
LS (g/cm
2) 1.05 (262) 0.71–1.50 1.00 (191) 0.66–1.49 0.93 (127) 0.60–1.40 0.89 (151) 0.57–1.31
FN (g/cm
2) 0.81 (99) 0.57–1.07 0.79 (107) 0.57–1.19 0.75 (20) 0.58–0.90 0.71 (22) 0.51–1.29
DHEAS (lmol/L) 4.91 (277) 0.20–20.0 4.04 (220) 0.30–11.60 3.60 (196) 0.40–20.0 3.19 (235) 0.20–13.4
Estradiol (pmol/L) 174.04 (197) 20.0–398.0 79.6 (189) 20.0–389.0 46.6 (194) 20.0–348.0 31.38 (238) 10.0–321.0
n, number of observations at each age group; BMD, bone mineral density; DHEAS, dehydroepiandrosterone sulfate; FN, femoral neck BMD; LS,
lumbar spine BMD
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123also had higher BMD at both FN and LS at the end of the
15-year follow-up.
The results from previous cross-sectional studies on the
effect of DHEAS on BMD in postmenopausal women with
DHEAS in the normal range are inconsistent. Our ﬁndings
concurwithstudiesthatreportapositiveassociationbetween
serum DHEAS and BMD [19–21]. Szathmari et al. [21]
found a positive relationship between DHEAS and BMD at
both FN and LS sites in 105 women aged 45–69 years, 76
postmenopausal and 29 premenopausal. In contrast, other
studies found no association of circulating DHEAS either
withabsolutevalueofBMD[22,23]orwithrateofboneloss
[24]. Zofkova et al. [22] found no association between
DHEAS and BMD at both FN and LS in 147 healthy or
osteoporotic but otherwise normal premenopausal (n = 26
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123and n = 13, respectively) or postmenopausal (n = 40 and
n = 68, respectively) women aged 40.1 ± 9.9 and
61.9 ± 8.9 years,respectively.Likewise,Murphyetal.[23]
found no signiﬁcant association in a cross-sectional study of
90 community-based women, all at least 1 year since their
last menstrual period, who were on average 9.6 years post-
menopausal (mean 9.6 ± 4.9 years, range 1–22). In a pro-
spective study of 256 men (aged 50–74 years) and 162
women(aged55–74 years),Barrett-Connoretal.[10]found
no association betweenDHEASlevels with BMD atanysite
ineither sex,bothbeforeandafter adjusting forage,obesity,
cigarette smoking, and use of antihypertensive medications.
A similar study [24] found an insigniﬁcant association
betweenDHEASandBMDattheFNandLSinapopulation-
based cohort of159, non-HRTuser, Australian-born women
who at baseline had a mean age of 50.0 years (SD = 2.4)
with reported menstruation within the previous 3 months.
The reason for the discrepancy is unclear; possible expla-
nations include small sample size, methodological differ-
ences [22, 23], and relatively short duration [10, 24].
Studies have suggested the complexity of the potential
mechanisms of the effects of DHEA on BMD loss. Estro-
gen may play a role in mediating the effect of DHEA on
bone loss. DHEA can be converted to estrogen, which is a
potential antiresorptive agent [25]. There was evidence for
a transient increase in serum estrogen for a few hours after
oral DHEA administration [26], and the correlations link-
ing serum DHEAS levels to bone turnover markers, BMD,
and osteoporotic fractures are strongest in elderly women,
in whom peripheral DHEA conversion is the only source of
estrogens [27]. However, the effect size of DHEAS on
bone loss was even increased after further adjustment for
estradiol in the current study, suggesting that DHEA may
have a direct effect on bone loss that is independent of
estradiol. There is also a possibility that the effect of
DHEA on bone was liaised by the increase in serum tes-
tosterone concentration that occurs in response to DHEA
[25]. Testosterone replacement has been shown to inhibit
bone resorption and stimulate formation in hypogonadal
men [28]. DHEA replacement resulted in a marked
increase in circulating IGF-I levels, which may exert ana-
bolic effects on bone [25]. Furthermore, treatment of oo-
phorectomized rats with DHEA increased BMD above that
of intact animals in parallel with the increase in alkaline
phosphatase, which may indicate a direct positive effect of
DHEA on osteoblasts [29]. DHEA administration reduced
the loss of cancellous bone volume in rats in a dose-
dependent manner by reducing bone remodeling [22].
However, ﬁndings in rodents are of limited signiﬁcance for
humans as DHEA physiology in humans is distinctly dif-
ferent from that in nonprimate mammals [30]. Further
studies are needed to elucidate the potential mechanisms
for the observed association.
There are some limitations in the current study. The
study population was all female; thus, the results may not
be generalizable. However, a similar signiﬁcant association
in males has been reported [31]. Multilevel analysis was
used to take account of the correlation between repeated
measures of FN and LS BMD, BMI, and HRT for the same
individual. Although missing outcome data can be com-
prised in this method of analysis, the ‘‘missing-at-random
assumption’’ might be violated if missing occurs system-
atically with regard to DHEAS levels. However, the
majority of loss to follow-up in the study was due to
censoring, and there was no difference in BMD, age, BMI,
and HRT use between women with and without DHEAS
measurements, suggesting that this is not an issue.
Although the models ﬁt the data properly, there was
inconsiderable variability of BMD between and within
subjects that remained unexplained; this could be due to
unknown genetic and environmental factors which were
not taken into account. In addition, since DHEAS was
measured only at baseline in this study, we could not
exclude the possibility that changes of DHEAS accompa-
nying BMD changes may be signiﬁcant for the regulation
of BMD.
In conclusion, our data suggest that a high serum
DHEAS level at baseline is associated with reduced bone
loss at both FN and LS and this association diminishes over
time. The nature of the association is unclear, but such an
association implies that women might beneﬁt from main-
taining a high level of DHEAS for their BMD.
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